ICER outlines alternatives to pharma rebates

Reflecting its growing standing as an opinion leader on all things drug price-related, the USA's Institute for Clinical and Economic Review (ICER) - in collaboration with the Office of Health Economics (OHE) - has published a white paper looking at alternative models for pharmaceutical rebates in the USA.

The paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future innovation.

The ICER claims that it could be a guide for policymakers as they consider multiple options, including those recently proposed by the Trump Administration.